Kamada (KMDA) Buy Rating Maintained at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Kamada (KMDA) Buy Rating Maintained at RBC Capital

Kamada (KMDA) Reports Holdings with EMA Over Proposed AATD Treatment

January 7, 2015 9:33 AM EST

Kamada (NASDAQ: KMDA) provides a clinical/regulatory update.

Kamada has held encouraging pre-submission meetings with its European rapporteur and co-rapporteur with regard to the Companys Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for its inhaled alpha-1 antitrypsin (AAT) for the treatment of alpha-1 antitrypsin deficiency (AATD). The co-rapporteurs advised that they would consider the entire study data once submitted, including post hoc analysis and will not reject the application simply because the primary endpoint of the study was not... More